A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer ?

ovartis Pharmaceuticals UK Limited0 个研究点目标入组 106 人开始时间: 2024年9月4日最近更新: 2024年9月9日

研究概览

暂无简介。

•1.Participants must be adults =18 years of age.
•2.Participants must have an ECOG performance status =1
•3.Participants must have histological confirmation of adenocarcinoma of the prostate
•4.Participants must be PSMA-positive per gallium (68Ga) gozetotide (also referred to as [68Ga]Ga-PSMA-11 or radiolabeled AAA517 and 68 Ga-PSMA-11) positron emission tomographic–computed tomographic (PET/CT) scans at baseline with at least 1 lesion showing intermediate or high uptake level (PSMA expression score 2 or 3 per PROMISE V2 criteria and no lesions meeting the size criteria as defined in the read rules showing PSMA expression scores 0 or 1 as determined by the central reader
•5.Participants must have a castrate level of serum/plasma testosterone (=50 ng/dL or =1.7 nmol/L) either by pharmaceutical or surgical methods
•6.Participants must have progressed only once on prior second generation ARPIs (abiraterone, enzalutamide, darolutamide, or apalutamide)

•1.Previous treatment with any of the following within 6 months of study enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation.
•2.Any previous radioligand therapy.
•3.Prior treatment with cytotoxic chemotherapy for metastatic castration-resistant or metastatic hormone-sensitive prostate cancer (mHSPC) (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy [including monoclonal antibodies]. [Note: Taxane exposure (maximum 6 cycles) in the adjuvant or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy. Prior treatment with sipuleucel-T is allowed].
•4.Any investigational agents within 42 days prior to the day of the first RLT treatment.

发起方

ovartis Pharmaceuticals UK Limited